<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613895</url>
  </required_header>
  <id_info>
    <org_study_id>IIT_DWP14012001</org_study_id>
    <nct_id>NCT04613895</nct_id>
  </id_info>
  <brief_title>Treatment Effect According to Timing of Administration of DWP14012 40 mg</brief_title>
  <official_title>A Multi-Center, Open-label, Randomized Trial to Evaluate the Efficacy and Safety Based on Timing of Administration of DWP14012 in Patients With Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to establish noninferiority of efficacy of DWP14012&#xD;
      (40 mg once daily) based on Timing of Administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will provide written informed consent for study participation and then undergo&#xD;
      appropriate screening. Subjects who meet the inclusion criteria and none of the exclusion&#xD;
      criteria will be randomized in a 1:1 ratio to either before meal group or after meal group.&#xD;
      Subjects will be stratified into two groups according to Los Angeles classification grades&#xD;
      (LA grades) A/B or C/D, as determined by upper gastrointestinal (GI) endoscopy. Subjects will&#xD;
      visit the site at Week 2 for endoscopic assessment. Subjects whose mucosal breaks have&#xD;
      completely healed will be prematurely withdrawn and considered to have reached end of&#xD;
      treatment. Subjects whose mucosal breaks have not healed will continue to receive IPs for an&#xD;
      additional 2 weeks and will visit the site for endoscopic assessment at Week 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 17, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>healing rate at 4 week</measure>
    <time_frame>4 week</time_frame>
    <description>Cumulative healing rate of erosive esophagitis at 4 week by endoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>healing rate at 2 week</measure>
    <time_frame>2 week</time_frame>
    <description>Cumulative healing rate of erosive esophagitis at 2 week by endoscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>fed state group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>just after a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fasted state group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>before a meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks</description>
    <arm_group_label>fed state group</arm_group_label>
    <other_name>fed state</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>DWP14012 40 mg, orally, once daily before a meal up to 4 weeks</description>
    <arm_group_label>fasted state group</arm_group_label>
    <other_name>fasted state</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 19 and 75 years old based on the date of written agreement&#xD;
&#xD;
          -  Those who have been diagnosed with erosive esophagitis of LA Grade A-D on the upper&#xD;
             gastrointestinal endoscopy&#xD;
&#xD;
          -  Those who experienced symptoms of heartburn or acid regurgitation within the last 7&#xD;
             days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have undergone gastric acid suppression or gastric, esophageal surgery&#xD;
&#xD;
          -  Those who with clinically significant liver, kidney, nervous system, respiratory,&#xD;
             endocrine, hematologic, cardiovascular, urinary system disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HOJIN LEE</last_name>
    <phone>+82-2-550-8651</phone>
    <email>hjlee200@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

